anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Moxifloxacin
Trial phase: Phase 1
ATC code: J01MA14 | S01AE07
SMILES: [H][C@@]12CCCN[C@]1([H])CN(c1c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c1OC)C2
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Single 400mg dose of active comparator moxifloxacin (open label)

Moxifloxacin 400mg: Active comparator with known effect on QT interval
Eligibility criteria:
Inclusion Criteria:

1. Males or females, of any race, between 18 and 55 years of age, inclusive, at Screening.
2. Body mass index (BMI) between 18.0 and 33.0 kg/m2, inclusive, at Screening
3. In good health

Exclusion Criteria:

1. An uninterpretable or abnormal ECG at Screening and/or Check in
2. History of risk factors for Torsades de Pointes
3. sustained supine systolic blood pressure >140 mmHg or <90 mmHg
4. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
5. Female subjects who are pregnant (or planning to become pregnant within 90 days after the final dose administration) or are currently lactating
6. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study
Intervention: Icosabutate
Trial phase: Phase 1
SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCOC(CC)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Likely therapeutic dose of NST-4016

NST-4016 600mg: Likely maximum therapeutic dose of NST-4016
Eligibility criteria:
Inclusion Criteria:

1. Males or females, of any race, between 18 and 55 years of age, inclusive, at Screening.
2. Body mass index (BMI) between 18.0 and 33.0 kg/m2, inclusive, at Screening
3. In good health

Exclusion Criteria:

1. An uninterpretable or abnormal ECG at Screening and/or Check in
2. History of risk factors for Torsades de Pointes
3. sustained supine systolic blood pressure >140 mmHg or <90 mmHg
4. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
5. Female subjects who are pregnant (or planning to become pregnant within 90 days after the final dose administration) or are currently lactating
6. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study
Intervention: Icosabutate
Trial phase: Phase 1
SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCOC(CC)C(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 32
Group description: Supratherapeutic dose of NST-4016

NST-4016 2000mg: Supratherapeutic dose of NST-4016
Eligibility criteria:
Inclusion Criteria:

1. Males or females, of any race, between 18 and 55 years of age, inclusive, at Screening.
2. Body mass index (BMI) between 18.0 and 33.0 kg/m2, inclusive, at Screening
3. In good health

Exclusion Criteria:

1. An uninterpretable or abnormal ECG at Screening and/or Check in
2. History of risk factors for Torsades de Pointes
3. sustained supine systolic blood pressure >140 mmHg or <90 mmHg
4. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
5. Female subjects who are pregnant (or planning to become pregnant within 90 days after the final dose administration) or are currently lactating
6. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study
Intervention: Caffeine Citrate
Trial phase: Early Phase 1
SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.

Caffeine Citrate: Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
Eligibility criteria:
Inclusion Criteria:

Adult (>/= 18 years old) undergoing non-cardiac, non-neurologic, non-major vascular surgery requiring general anesthesia

Exclusion Criteria:

Emergency surgery
Cognitive impairment precluding capacity for informed consent
Uncontrolled cardiac arrhythmias
Seizure disorders
Preoperative opioid use
Diabetes
Liver failure
Pregnancy
Breastfeeding
Severe visual or auditory impairment (may hinder cognitive function testing)
Patients unable to speak English.
Intervention: Cefazolin
Trial phase: Phase 2
ATC code: J01DB04
SMILES: [H][C@]12SCC(CSc3nnc(C)s3)=C(C(=O)O)N1C(=O)[C@H]2NC(=O)Cn1cnnn1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: -Women randomized to prophylactic antibiotics will receive a cefazolin as per ACOG guidelines.
Eligibility criteria:
Inclusion Criteria:

All women, >=18 undergoing vulvar surgery
Biopsy proven benign or premalignant lesion requiring surgical management.
Women of childbearing age will be required to have a negative human chorionic gonadotropin (HCG) test within seven days of surgery.
Scheduled to undergo surgical management for their vulvar disease supervised by a faculty member within the Division of OBGYN at Washington University School of Medicine
Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

Women who are pregnant
Women scheduled to undergo a radical vulvectomy
Women scheduled to undergo a concomitant graft, flap or plastic surgery
Women <18 years of age
History of prior vulvar radiation
Inability to sign an informed consent form prior to registration on study
Inability to understand spoken or written English
Prisoner
Intervention: Acetylcysteine
Trial phase: Phase 4
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or "mucus plugging." Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs.

N-acetylcysteine: Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
Eligibility criteria:
Inclusion Criteria:

Male or female between the ages of 18 and 80 years of age at Visit 1
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
Able to perform reproducible spirometry according to ATS criteria
Physiological evidence of airflow obstruction (FEV1 bronchodilator reversibility of ≥ 12% or hyperreactivity to methacholine reflected by a methacholine PC20 ≤ 16 mg/mL)
Clinical history of asthma per patient report or medical record
Pre-bronchodilator FEV1 > 35% predicted
Post-bronchodilator FEV1 > 40% but < 90% predicted
Asthma requiring treatment with inhaled corticosteroids (ICS) for 3 months or greater
CT mucus score > 3

Exclusion Criteria:

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Smoking of tobacco or other recreational inhalants in last year and/or >10 pack-year smoking history
Current participation in an investigational drug trial
Other chronic pulmonary disorders, including (but not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and at the PI's discretion), severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways
Unwillingness to follow study procedures
History of allergy or intolerance to study drug
Any other criteria that places the subject at unnecessary risk according to the judgment of the Principal Investigator
Intervention: Buspirone
Trial phase: Phase 2
ATC code: N05BE01
SMILES: O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks

Buspirone: Buspirone tablet
Eligibility criteria:
Inclusion Criteria:

Age 18 to 85 years of age at initial screening interview
Symptoms compatible with gastroparesis or other functional gastric disorder for at least 3 months (does not have to be contiguous) prior to initial screening interview
Diagnosis of either diabetic or idiopathic gastroparesis
Delayed or normal gastric emptying retention on screening 4-hour Gastric Emptying Scintigraphy test
Symptoms of gastroparesis measured by the 9-item PAGI-SYM Gastroparesis Cardinal Symptom Index (GCSI) total score > 2.0 at enrollment
Symptomatic with postprandial fullness/early satiety severity at enrollment using the PAGI-SYM GCSI post-prandial fullness/early satiety subscore ≥ 3
Upper endoscopy or upper GI series without ulcers or mass lesions in the 2 years prior to enrollment

Exclusion Criteria:

Post-surgical gastroparesis, including prior pyloromyotomy, pyloric resection, vagotomy, bariatric surgery or post-Nissen fundoplication
Another active disorder which could explain symptoms in the opinion of the investigator
Concurrent use of opiate narcotic analgesics more than 3 days per week
Significant hepatic injury as defined by alanine aminotransferase (ALT) elevation of greater than twice the Upper Limit of Normal (ULN) or a Child-Pugh score of 10 or greater
Significant renal impairment as defined by serum creatinine > 3.0
Uncontrolled diabetes defined as HbA1c (%) of 10% or more within 60 days of enrollment
Allergy to buspirone
Concurrent or prior use (within 30 days) of monoamine oxidase (MAO) inhibitors
Concurrent or prior use (within 30 days) of benzodiazepines
Concurrent or prior use (within 30 days) of buspirone, warfarin, haloperidol, and drugs to treat seizures (e.g., phenytoin and carbamazepine)
Women breast feeding or known to be pregnant
Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study
Failure to give informed consent
Intervention: Apremilast
Trial phase: Phase 4
ATC code: L04AA32
SMILES: CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: Otezla: Otezla 30mg BID Enstilar QD
Eligibility criteria:
Inclusion Criteria:

Male or female adult ≥ 18 years of age;
Diagnosis of chronic plaque-type psoriasis

Moderate to severe plaque type psoriasis as defined at baseline by:

PGA score of 3 or greater
BSA affected by plaque-type psoriasis of 10% or greater
PASI ≥ 12
Able and willing to give written informed consent prior to performance of any study-related procedures
Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

Exclusion Criteria:

Other than psoriasis, any clinically significant (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is uncontrolled.
Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or guttate psoriasis) or drug induced psoriasis
Subjects who previously used any biologic agent for psoriasis.
Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and cyclosporine).
Patient used topical therapies to treat psoriasis on the hands and/or feet within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
Patient received UVB phototherapy within 2 weeks of Baseline.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: These patients receive an interscalene block with liposomal bupivacaine.

liposomal bupivacaine: Experimental
Eligibility criteria:
Inclusion Criteria:

Adult patients aged greater than 18 years of age that are undergoing arthroscopic rotator cuff surgery

Exclusion Criteria:

Patients with allergy to local anesthetics
Patients with daily use of opioids for more than 3 weeks prior to surgery
Patients who refuse
Patients with coagulopathy
Patients who are non-english speaking
Patients who do not have access to a telephone
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: These patients receive an interscalene block with bupivacaine.

Bupivacaine: Active Comparator
Eligibility criteria:
Inclusion Criteria:

Adult patients aged greater than 18 years of age that are undergoing arthroscopic rotator cuff surgery

Exclusion Criteria:

Patients with allergy to local anesthetics
Patients with daily use of opioids for more than 3 weeks prior to surgery
Patients who refuse
Patients with coagulopathy
Patients who are non-english speaking
Patients who do not have access to a telephone
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 37
Group description: 20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.

Bupivacaine: interscalene block with bupivacaine
Eligibility criteria:
Inclusion Criteria:

All adult patients aged greater than 18 years of age that are undergoing total or reverse total shoulder arthroplasty

Exclusion Criteria:

Patients with allergy to local anesthetics, daily use of opioids for more than 3 weeks prior to surgery, patient refusal, patient with coagulopathy, non-english speaking patients, and those who do not have access to a telephone.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 33
Group description: 10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance

liposome bupivacaine: interscalene block with liposomal bupivacaine plus bupivacaine
Eligibility criteria:
Inclusion Criteria:

All adult patients aged greater than 18 years of age that are undergoing total or reverse total shoulder arthroplasty

Exclusion Criteria:

Patients with allergy to local anesthetics, daily use of opioids for more than 3 weeks prior to surgery, patient refusal, patient with coagulopathy, non-english speaking patients, and those who do not have access to a telephone.
Intervention: Venlafaxine Hydrochloride
Trial phase: Not Applicable
SMILES: COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 43
Group description: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.

Venlafaxine hydrochloride capsules: The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
Eligibility criteria:
Inclusion Criteria：

The first stroke of the left single subcortical areas, within 72hours.
Primary school or higher level,aged between 18-75, native language Chinese
According to the commonly used eye chart examination, the corrected visual acuity is more than 1.0.
According to the Edinburgh Handedness Questionnaire (EHQ) as the right handed.
The language function was normal before the onset. After the onset, the language function was mildly to moderately impaired with Western Aphasia Battery (WAB) ( Aphasia Quotient (AQ) between in 60 to 88)
The patient cooperate with the examination, they and their guardian signed the informed consent

Exclusion Criteria：

History of organic diseases of the nervous system and history of craniocerebral trauma.
History of epilepsy and psychosis.
History of material dependence.
Decompensation of important organ function.
Hamilton Depression Scale(HAMD )>8 points.
Hamilton Anxiety Scale(HAMA )>7 points.
The Mini-Mental State Examination (MMSE)score <20 points.
Dysphagia(difficult to take capsules).
A history of allergens in component of venlafaxine.
Pregnant women and breast-feeding women.
Contraindication of MRI.
Intervention: Amitriptyline
Trial phase: Phase 2
ATC code: N06AA09 | N06CA01
SMILES: CN(C)CCC=C1c2ccccc2CCc2ccccc21
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Participants initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose was increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline was reduced to 25 mg daily during the two week Taper Period.
Eligibility criteria:
Inclusion Criteria:

Subjects with Type 1 Diabetes Mellitus for at least 5 years or more
Age between 21 to 60 years old
HbA1c less or equal to 9% with the latest measurement within the last 3 months
Use of real time Continuous Glucose Monitoring (rtCGM) providing continuous glucose data points for at least 3 months, and at least 80% of CGM readings available over the last 2-week period
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines

Exclusion Criteria:

Ongoing or recent history of major depressive disorder, or other ongoing major psychiatric disorders
History of anti-depressant use within the last three months
Insulin pump linked to a CGM with programmed automatic insulin adjustment or suspension
History of advanced cardiac, liver, kidney or neurological disease
Active malignancy
Uncontrolled Human Immunodeficiency Virus diseases
Advanced diabetic retinopathy, neuropathy, or nephropathy
Frequent acetaminophen use which can disrupt CGM accuracy
Pregnancy or female of child-bearing potential unable to practice effective contraception during the study period
Breastfeeding female, or female with prospective plan to initiate breastfeeding
Ongoing history of alcohol abuse
Contraindication to amitriptyline use, including hypersensitivity to amitriptyline or any component of the formulation, co-administration with or within 14 days of Monoamine Oxidase Inhibitors and co-administration with cisapride
Inability to understand or cooperate with study procedures, including taking study drugs and recording hypoglycemic symptoms.

The participants meeting the above criteria will enter "Run-in Period". At the Visit 2, the following additional exclusion criteria will be applied before study drug randomization:

< 80% of CGM readings available over the last 2-week period
Time spent in hypoglycemia (i.e., < 70 mg/dL) for < 5% over a 2-week period on based on CGM reading.
Intervention: Deferiprone
Trial phase: Phase 4
ATC code: V03AC02
SMILES: Cc1c(O)c(=O)ccn1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 32
Group description: Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses

Deferiprone oral solution: Liquid formulation of deferiprone, with a concentration of 80 mg/mL
Eligibility criteria:
Inclusion Criteria:

Male or female aged ≥ 6 months to < 10 years
Confirmed diagnosis of beta-thalassemia, as determined by high performance liquid chromatography (HPLC) or DNA testing
Started on a red blood cell (RBC) transfusion regimen, with a minimum of 2 transfusions already completed
Screening level of serum ferritin (SF) greater than >200 μg/L but not more than 600 μg/L. Since SF level may be impacted by the presence of infection, it must additionally be verified that the child has had no signs of infection in the previous 7 days, including the day of screening, and that the level of C-reactive protein (CRP) is no greater than 20% higher than the normal range for the patient's age. If there are signs of infection and/or the CRP level is above this threshold, the SF level must be checked again a minimum of one week later.

Exclusion Criteria:

Prior use of iron chelation
Diagnosis of hepatitis B or C, or HIV infection
Evidence of abnormal liver or kidney function at screening: serum alanine transaminase (ALT) level > 5 times upper limit of normal or creatinine levels >2 times upper limit of normal
Disorders associated with neutropenia (absolute neutrophil count < 1.5 x 10^9/L) prior to the initiation of study medication
A serious, unstable illness, as judged by the investigator, during the previous 3 months before screening/baseline visit including but not limited to hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease.
Presence of any medical condition which in the opinion of the investigator would cause participation in the study to be unwise.
Intervention: Brimonidine Tartrate
Trial phase: Phase 3
SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: One drop of Brimonidine Tartrate Nanoemulsion 0.18% administered in each eye BID
Eligibility criteria:
Inclusion Criteria:

Men or women ≥ 18 years of age
Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus Group Revised Diagnostic criteria in at least one eye.
Ocular Discomfort score ≥ 3
Validated Bulbar Redness score ≥ 40 in both eyes
Subjects who are capable and willing to provide informed consent and follow study instructions
Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye
Women who are not pregnant or lactating or post-menopausal or have undergone a sterilization procedure

Exclusion Criteria:

Allergic to brimonidine or any similar products, or excipients of brimonidine
Currently receiving any brimonidine or other treatment for glaucoma
Receiving or have received any investigational drug or device within 30 days of screening
Current use of contact lenses 14 days prior to screening
Active ocular infection or ocular allergies
Any history of eyelid surgery or ocular surgery within the past 3 months
Corneal epithelial defect larger than 1 mm (squared) in either eye
Received corticosteroid-containing eye drops within 14 days prior to screening or planned use during the study
Any change in corticosteroid-containing eye drops, systemic corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®) or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30 days prior to screening or planned change during the study